U.S. markets closed

ProQR Therapeutics N.V. (PRQR)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
7.19-0.02 (-0.28%)
At close: 4:00PM EDT
7.00 -0.19 (-2.64%)
After hours: 07:16PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Relative Strength Index (RSI)

Relative Strength Index (RSI)

Previous Close7.21
Bid7.12 x 800
Ask7.48 x 900
Day's Range7.07 - 7.36
52 Week Range3.40 - 9.46
Avg. Volume3,467,542
Market Cap475.46M
Beta (5Y Monthly)0.51
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • What Kind Of Investors Own Most Of ProQR Therapeutics N.V. (NASDAQ:PRQR)?
    Simply Wall St.

    What Kind Of Investors Own Most Of ProQR Therapeutics N.V. (NASDAQ:PRQR)?

    Every investor in ProQR Therapeutics N.V. ( NASDAQ:PRQR ) should be aware of the most powerful shareholder groups...

  • ProQR (PRQR) Reports Q1 Loss, Misses Revenue Estimates

    ProQR (PRQR) Reports Q1 Loss, Misses Revenue Estimates

    ProQR (PRQR) delivered earnings and revenue surprises of -7.14% and -92.92%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

  • ProQR Therapeutics Stock Is Trading Higher On Antisense Oligonucleotide Development Pact

    ProQR Therapeutics Stock Is Trading Higher On Antisense Oligonucleotide Development Pact

    Yarrow Biotechnology Inc, a newly created company by RTW Investments LP, has in-licensed exclusive rights to ProQR Therapeutics N.V.'s (NASDAQ: PRQR) antisense oligonucleotide technology to develop and commercialize potential therapies for an undisclosed non-ophthalmic target. Under the terms of the agreement, ProQR is eligible to receive up to $115 million of upfront and milestone payments, plus single-digit percentage royalties on the net sales of any resulting products during the royalty term. ProQR will also have the right to receive an undisclosed percentage of equity in Yarrow. ProQR will be responsible for certain preclinical activities with reimbursement for the research costs by Yarrow. At the same time, Yarrow will be responsible for continuing the development of the program and commercialization activities. Gerard Platenburg, Chief Innovation Officer at ProQR, will join Yarrow's board of directors. Price Action: PRQR shares are up 1.58% at $6.46 on the last check Tuesday. See more from BenzingaClick here for options trades from BenzingaAbCellera-Lilly Partnered Second COVID-19 Antibody Enters Human TrialsSoleno Therapeutics' DCCR Treatment Shows Improvement In Multiple Behavioral Domains In Prader-Willi Syndrome Patients© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.